Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
Stephen HanauerP Rutgeerts

Abstract

The effect of different treatment regimens on antibody responses to infliximab and their clinical significance was examined by using data from ACCENT I. Patients with Crohn's disease (n = 573) received 5 mg/kg infliximab (week 0) and then were randomly assigned to blinded infusions at weeks 2 and 6 and every 8 weeks until week 46 of placebo (group I), 5 mg/kg infliximab (group II), or 5 mg/kg infliximab at weeks 2 and 6, followed by 10 mg/kg thereafter (group III). At week 14 or later, patients losing response could cross over to episodic infliximab treatment increased by 5 mg/kg. Samples for antibody determination were collected before the first infusion and at weeks 14, 22, 54, 62, 72, and, if applicable, before and after crossover. Through week 72, antibodies to infliximab were detected in 30%, 10%, and 7% of groups I, II, and III, respectively (P < 0.0001). Patients receiving immunomodulators had a lower incidence of antibodies compared with patients receiving infliximab alone (10% and 18%, respectively; P = 0.02). Antibodies were associated with a 12% absolute increase in infusion reactions but no increase in serious infusion reactions or serum sickness-like reactions. In the overall population, similar proportions of anti...Continue Reading

References

Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Dec 1, 1983·Diabetologia·S E FinebergS Hufferd
Jan 1, 1996·Annual Review of Immunology·M FeldmannR N Maini
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Nov 5, 2003·Gastroenterology·Chinyu G Su, Gary R Lichtenstein
Apr 13, 2004·Arthritis and Rheumatism·R N MainiUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

❮ Previous
Next ❯

Citations

Feb 17, 2007·Inflammatory Bowel Diseases·Wojciech Blonski, Gary R Lichtenstein
Feb 20, 2007·Inflammatory Bowel Diseases·Giovanni LatellaRenzo Caprilli
May 8, 2007·Inflammatory Bowel Diseases·Miguel RegueiroScott Plevy
Nov 21, 2007·Inflammatory Bowel Diseases·Arun Swaminath, Simon Lichtiger
Mar 25, 2009·Inflammatory Bowel Diseases·Stephen B Hanauer
May 23, 2009·Inflammatory Bowel Diseases·Jason E GonzagaDavid G Binion
Oct 17, 2009·Inflammatory Bowel Diseases·Hussila KeshawRichard M Day
Sep 18, 2010·Inflammatory Bowel Diseases·Jason M SwogerWilliam J Sandborn
Feb 22, 2011·Inflammatory Bowel Diseases·Michael A KammStephen B Hanauer
Apr 13, 2011·Inflammatory Bowel Diseases·Walter ReinischBruce E Sands
May 28, 2011·Inflammatory Bowel Diseases·M ChaparroJ P Gisbert
Oct 25, 2011·Inflammatory Bowel Diseases·Jean-Frédéric ColombelAnne M Robinson
Sep 22, 2011·Inflammatory Bowel Diseases·Charlotte I de BieLissy de Ridder
Feb 22, 2012·Inflammatory Bowel Diseases·Casper SteenholdtMark A Ainsworth
Sep 17, 2009·European Journal of Clinical Pharmacology·Adedigbo A FasanmadeHonghui Zhou
May 10, 2011·Internal and Emergency Medicine·Antonio Di SabatinoGino Roberto Corazza
Nov 2, 2011·Internal and Emergency Medicine·Antonio Di SabatinoGino R Corazza
Nov 30, 2005·Current Gastroenterology Reports·Laurence J Egan, William J Sandborn
Apr 2, 2008·Current Gastroenterology Reports·Stephen B Hanauer
Nov 14, 2008·Current Gastroenterology Reports·Stephen B Hanauer
May 26, 2005·Current Treatment Options in Gastroenterology·Win J Travassos, Adam S Cheifetz
Aug 12, 2006·Current Treatment Options in Gastroenterology·Wojciech Blonski, Gary R Lichtenstein
Dec 1, 2007·Journal of Crohn's & Colitis·Konstantinos KatsanosGert Van Assche
Apr 4, 2006·Nature Clinical Practice. Gastroenterology & Hepatology·John T Chang, Gary R Lichtenstein
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Apr 16, 2010·The New England Journal of Medicine·Jean Frédéric ColombelUNKNOWN SONIC Study Group
Nov 6, 2009·Tissue Engineering. Part C, Methods·Keen Shawn FoongRichard M Day
May 4, 2005·Inflammatory Bowel Diseases·David S Fefferman, Richard J Farrell
Dec 2, 2005·Current Opinion in Gastroenterology·Wojciech Blonski, Gary R Lichtenstein
Jun 9, 2006·Current Opinion in Gastroenterology·Gert Van AsschePaul Rutgeerts
Apr 16, 2013·Inflammatory Bowel Diseases·Yi-Lin ChiuSusan K Paulson
Sep 3, 2013·Current Opinion in Pediatrics·Imad Absah, Michael Stephens
Sep 22, 2009·Alimentary Pharmacology & Therapeutics·A OussalahL Peyrin-Biroulet
Feb 28, 2007·Clinical and Experimental Pharmacology & Physiology·Tamaki TakagiMakoto Sawada
Dec 23, 2011·Journal of Gastroenterology and Hepatology·Crispin CorteRupert W Leong
Oct 14, 2006·Annals of the Rheumatic Diseases·D E FurstM H Weisman
Mar 30, 2007·Annals of the Rheumatic Diseases·Mahboob U RahmanRene Westhovens
Nov 21, 2007·Annals of the Rheumatic Diseases·D E FurstM E Weinblatt
Mar 20, 2010·Annals of the Rheumatic Diseases·Nicolino RupertoUNKNOWN Pediatric Rheumatology Collaborative Study Group (PRCSG)

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved